Vor Biopharma
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 168
- Market Cap
- $60.8M
- Introduction
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Cambridge, MA.
Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Biological: VCAR33
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Vor Biopharma
- Target Recruit Count
- 24
- Registration Number
- NCT05984199
- Locations
- ๐บ๐ธ
Stanford Cancer Institute, Stanford, California, United States
๐บ๐ธUniversity of California San Diego Moores Cancer Center, La Jolla, California, United States
๐บ๐ธIcahn School of Medicine at Mount Sinai, New York, New York, United States
A Long-term Follow-up Study of Patients Who Received VOR33
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Genetic: VOR33
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Vor Biopharma
- Target Recruit Count
- 36
- Registration Number
- NCT05309733
- Locations
- ๐บ๐ธ
University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
๐บ๐ธUniversity of California San Diego Moores Cancer Center, La Jolla, California, United States
๐บ๐ธMiami Cancer Institute, Miami, Florida, United States
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
- Conditions
- Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
- Interventions
- Biological: VOR33Drug: Mylotarg
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Vor Biopharma
- Target Recruit Count
- 24
- Registration Number
- NCT04849910
- Locations
- ๐บ๐ธ
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
๐บ๐ธUniversity of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States
๐บ๐ธUniversity of California San Diego Moores Cancer Center, La Jolla, California, United States